Moderna's Cancer Vaccine Shows Promise, Stock Valuation Raises Concerns
Moderna's stock has surged over 600% this year, reaching a market cap close to 90000 million dollars, driven by positive clinical trial results for its cancer vaccine, intismeran, developed in collaboration with Merck. On Aug. 19, phase 3 trial results indicated that intismeran, when combined with Merck's Keytruda, significantly reduced the risk of death and cancer recurrence in melanoma patients. Despite the promising results, the vaccine has not yet received approval, and there are concerns about the stock's inflated valuation. Investors may be overestimating the potential for intismeran to treat multiple cancers, which remains uncertain. Additionally, the production of a personalized cancer vaccine at scale poses operational challenges and costs. The profit-sharing agreement between Moderna and Merck could further limit Moderna's long-term profitability. Given these factors, the current stock price may not be sustainable, and potential investors should exercise caution.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

NVIDIA Launches Nemotron for Science to Accelerate Scientific Discoveries with Intelligent Agents

FDA Rejects Approval of Kangfang Biotech's Cancer Drug Ivonescimab

Former Employee Sues Ethereum Foundation, Claims Retaliatory Dismissal After Protesting 'Seppuku' Clause

BRT.Fit Founder Calls for Incorporating Exercise Habits into Cancer Prevention

Nixo sues Ethereum Foundation, Vitalik Buterin over 'suicide pledge' claim

U.S. Senate Rejects Long-Term Regulation Legislation for the Cryptocurrency Industry

Proteomic clocks link accelerated aging to higher risk of death and disease

Aging is not linear: cells go through coordinated stages of deterioration

Trump and Islamophobia: The Chorus That No Longer Mobilizes Votes

Jennifer Tilly Earns Up to $10 Million a Year from The Simpsons Without Ever Participating: Her Story

Tesla Plans to Invest €3 Billion to Expand Berlin Factory, Aiming for Annual Production of 1 Million Cybercabs

Former OpenAI Researcher Aschenbrenner's Hedge Fund Bets on AI Again Before October Market Crash

Tradeweb Launches AI Assistant for U.S. Treasury Traders, Over Ten Companies Testing

NYSE Parent Company Considers Operating Solana Validators

These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys

Aave’s revenue falls $10M in Q3, but one metric tells a new story

4 Chip Stocks Down as Much as 36% From Their Highs to Buy and Hold for the Next Decade

Unocoin Estimates $200,000 Loss as Backup-Key Finding Explains Wallet Transfers

Strategy planned to slow STRC buybacks near $100 but spent another $1.4 billion instead

Michael Burry Cashed In Caterpillar Puts After a Nearly 4x Gain Even as CAT Stock Fell 10% in Its Worst Week in 18 Months. Is Caterpillar Still Overvalued, or Did Burry Just Lock In the Easy Money?

CoinShares Enters Russell Index Review as Crypto Stocks Seek Broader Investor Access

ARTEX AI tool breaches networks in under 3 hours, FBI warns

Tether invests $15M in Nomad as Brazil tightens payment rules

XRP’s proposed upgrade could improve trading without boosting token demand

Nike's Turnaround Is Taking Longer Than Expected. These 3 Stocks May Be Better Buys.

Clarity Act Defeat ‘Failure of American Leadership’: Trump’s Former Crypto Chief

TRON to overtake JD.com? Justin Sun points to 500-person team

Where Will Eli Lilly Be in 10 Years? 1 Clue: Its Next Potential Blockbuster Just Beat Ozempic Head-to-Head

3 Financial Stocks to Buy and Hold That Turned $1,000 Into More Than $5,000 Over the Past Decade, Counting Dividends







